Screener / SEC EDGAR /CIK 0001515673 /10-K filed Feb 18, 2026, compared with Feb 19, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Ultragenyx Pharmaceutical Inc. RARE

Compare with peers Embed
SEC comment letters, last 20 years

1 review of RARE's filings by SEC staff

UPLOAD and CORRESP
Reviews 1 latest letter Apr 22, 2024
Questions asked 1 each answered in the company's own letter
No closing letter 0 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 1 UPLOAD
  2. 2. Questions in them 1 numbered comments
  3. 3. Company replies 1 CORRESP
  4. 4. Reviews closed 1 of 1 closing letter

Half the closed reviews took 49 days or less from the first letter to the closing letter.

Form 10-K

2024-04-22 to 2024-06-10 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2024-06-10
Results discussion (MD&A)
Management's Discussion and Analysis of Financial Condition and Results of Operations, page
SEC asked
Please address the following regarding your table of research and development (R&D) expenses on page 75: • Tell us and revise your future filings to clearly disclose the extent to which you track any of your R&D expenses at the individual product candidate level, as you previously disclosed in your 2020 Form 10-K.
Rest of the question

• If so, revise your future filings to separately quantify your R&D expenses for amounts tracked by product candidate. • Please provide us with your proposed disclosure in your response. In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

RARE answered
The Company acknowledges and appreciates the Staff’s comment and respectfully advises the Staff that although the Company does track and allocate certain operational research and development (“R&D”) costs at the individual product candidate level, the Company does not fully track and allocate total R&D expenses at the individual product candidate level.

Specifically, the Company tracks costs to conduct clinical studies, including expenses incurred with clinical research organizations, direct manufacturing costs, and personnel costs such as employee salaries and benefits at the individual
Rest of the answer

product candidate level. Certain other R&D expenses, such as costs associated with Chemistry, Manufacturing and Controls (CMC costs), which are primarily purchases of materials for

Ultragenyx.com our internal gene therapy manufacturing activities, are generally spread across multiple product candidates, and as such are not tracked at the individual product level. As the Company is a diversified commercial company with significant ongoing R&D efforts, potential product candidates are pooled together and resources shared across these candidates as they progress through the R&D pipeline.

In response to the Staff’s comment, the Company proposes to include additional disclosure under the subheading “ – Research and Development

Expenses” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s future periodic reports, beginning with the Company’s Quarterly Report on Form 10-Q for the three and six months ended June 30, 2024, that includes an additional breakout of operational expenses that are allocable to and analyzed by specific individual product candidates in each product category and additional detail regarding how the Company manages its R&D expenses. The proposed additional disclosure would be substantially in the form set forth on Exhibit A attached hereto. The Company believes the proposed additional disclosure reflects the way management views and manages the Company’s R&D activities and business. The Company also believes that the proposed additional disclosure will provide further context to enhance an investor’s understanding of the Company’s use and expected use of resources in connection with its R&D programs.

***

Please advise us if we can provide any further information or assistance to facilitate your review. Please direct any further comments or questions regarding this response letter to the undersigned at [email protected] or Karah Parschauer, Executive Vice President, Chief Legal Officer & Corporate Affairs at [email protected].

Read in the reply
In its next report

First report after the company's reply of May 17, 2024: 10-Q filed Aug 2, 2024 ↗, against the 10-Q filed Nov 3, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2024-06-10

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 3 letters filed since 2024-04-22. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RARE/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.